Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?

被引：0
|
作者：
Barakat, Amr F. [1 ]
Mahmoud, Ahmed N. [2 ]
Elgendy, Islam Y. [2 ]
机构：
[1] Cleveland Clin Fdn, Dept Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2017年 / 239卷
关键词：
CONTROLLED RANDOMIZED-TRIALS; CARDIOVASCULAR SAFETY; INHIBITORS;
D O I：
10.1016/j.ijcard.2017.01.144
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 43 条
  • [41] Use of i-SGLT2 in patients with type 2 Diabetes Mellitus, cardiovascular disease and heart failure: what evidence do we have available?
    Martinez, Felipe
    Garcia Brasca, Daniela F.
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2020, 49 : 19 - 23
  • [42] Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 1 diabetes
    Zhou, Yue
    Geng, Zhuang
    Wang, Xiang
    Huang, Yajing
    Shen, Liyan
    Wang, Yangang
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (02)
  • [43] THE GLUCOSE-LOWERING THERAPY STRUCTURE IN SPECIAL GROUPS OF TYPE 2 DIABETES MELLITUS PATIENTS BASED ON DATA FROM THE MOSCOW REGION REGISTER
    Misnikova, Inna, V
    Kovaleva, Yulia A.
    Isakov, Mikhail A.
    Dreval, Alexander, V
    DIABETES MELLITUS, 2019, 22 (03): : 206 - 216
12345